|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | ALTANA Pharma |
|---|---|
| Information provided by: | ALTANA Pharma |
| ClinicalTrials.gov Identifier: | NCT00062582 |
Purpose
The aim of the study is to compare the effect of roflumilast and placebo on the lung function in patients with COPD.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Obstructive Pulmonary Disease COPD |
Drug: Roflumilast |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
| Official Title: | A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 Mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
Main Exclusion Criteria:
Contacts and Locations
Show 37 Study Locations| Principal Investigator: | Douglas S. Helmersen, Prof. Dr. | Peter Lougheed Center; 3500-26th Ave. NE, Calgary, Canada |
More Information
| Study ID Numbers: | BY217/M2-110 |
| Study First Received: | June 9, 2003 |
| Last Updated: | December 15, 2006 |
| ClinicalTrials.gov Identifier: | NCT00062582 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Roflumilast Chronic Obstructive Pulmonary Disease COPD |
|
Signs and Symptoms Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases |
Respiration Disorders Signs and Symptoms, Respiratory Pulmonary Disease, Chronic Obstructive |